Risk of unintended pregnancy among women with systemic lupus erythematosus

Arthritis Care and Research

Volumn 59, Issue 6, 2008, Pages 863-866

  Schwarz, Eleanor Bimla ^a,b   Manzi, Susan ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; BIRTH CONTROL; EMERGENCY CONTRACEPTION; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; RISK ASSESSMENT; SEXUAL BEHAVIOR; SYSTEMIC LUPUS ERYTHEMATOSUS; UNPLANNED PREGNANCY;

ADULT; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREGNANCY; PREGNANCY, UNWANTED; UNSAFE SEX;

EID: 45349096947     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23712     Document Type: Article

References (39)

1. Chakravarty EF, Nelson L, Krishnan E. Obstetric hospitalizations in the United States for women with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 2006;54:899-907.
2. Clowse ME, Magder LS, Witter F, Petri M. The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 2005;52:514-21.
3. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. Philadelphia: Lippincott Williams & Wilkins; 2002.
4. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005;353:2550-8.
5. Sanchez-Guerrero J, Uribe AG, Jimenez-Santana L, Mestanza-Peralta M, Lara-Reyes P, Seuc AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. N Engl J Med 2005;353:2539-49.
6. Tarr T, Lakos G, Bhattoa HP, Szegedi G, Shoenfeld Y, Kiss E. Primary antiphospholipid syndrome as the forerunner of systemic lupus erythematosus. Lupus 2007;16:324-8.
7. Jimenez S, Garcia-Criado MA, Tassies D, Reverter JC, Cervera R, Gilabert MR, et al. Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome. Rheumatology (Oxford) 2005;44:756-61.
8. World Health Organization. Low-dose combined oral contraceptives. In: Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: Reproductive Health and Research WHO; 2004.
9. Almehed K, Forsblad d'Elia H, Kvist G, Ohlsson C, Carlsten H. Prevalence and risk factors of osteoporosis in female SLE patients: extended report. Rheumatology (Oxford) 2007;46:1185-90.
10. Scholes D, Lacroix AZ, Ott SM, Ichikawa LE, Barlow WE. Bone mineral density in women using depot medroxyprogesterone acetate for contraception. Obstet Gynecol 1999;93:233-8.
11. Schwarz E, Lohr P. Oral contraceptives in women with systemic lupus erythematosus [letter]. N Engl J Med 2006;354:1203-4.
12. Hatcher R, Trussell J, Stewart F, Nelson A, Cates W, Guest F, et al. Contraceptive technology. 18th ed. New York: Ardent Media; 2004.
13. Finer LB, Henshaw SK. Abortion incidence and services in the United States in 2000. Perspect Sex Reprod Health 2003;35:6-15.
14. Trussell J, Vaughan B. Contraceptive failure, method-related discontinuation and resumption of use: results from the 1995 National Survey of Family Growth. Fam Plann Perspect 1999;31:64-72.
15. St James PJ, Younger MD, Hamilton BD, Waisbren SE. Unplanned pregnancies in young women with diabetes: an analysis of psychosocial factors. Diabetes Care 1993;16:1572-8.
16. Holing EV, Beyer CS, Brown ZA, Connell FA. Why don't women with diabetes plan their pregnancies? Diabetes Care 1998;21:889-95.
17. Schwarz EB, Maselli J, Gonzales R. Contraceptive counseling of diabetic women of reproductive age. Obstet Gynecol 2006;107:1070-4.
18. Chuang CH, Chase GA, Bensyl DM, Weisman CS. Contraceptive use by diabetic and obese women. Womens Health Issues 2005;15:167-73.
19. Mintz G, Gutierrez G, Deleze M, Rodriguez E. Contraception with progestagens in systemic lupus erythematosus. Contraception 1984;30:29-38.
20. World Health Organization. Intrauterine devices. In: Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: Reproductive Health and Research WHO; 2004.
21. Bahamondes L, Espejo-Arce X, Hidalgo MM, Hidalgo-Regina C, Teatin-Juliato C, Petta CA. A cross-sectional study of the forearm bone density of long-term users of levonorgestrel-releasing intrauterine system. Hum Reprod 2006;21:1316-9.
22. Pisoni CN, Cuadrado MJ, Khamashta MA, Hunt BJ. Treatment of menorrhagia associated with oral anticoagulation: efficacy and safety of the levonorgestrel releasing intrauterine device (Mirena coil). Lupus 2006;15:877-80.
23. Tewari R, Kay VJ. Compliance and user satisfaction with the intra-uterine contraceptive device in Family Planning Service: the results of a survey in Fife, Scotland, August 2004. Eur J Contracept Reprod Health Care 2006;11:28-37.
24. Varney SJ, Guest JF. Relative cost effectiveness of Depo-Provera, Implanon, and Mirena in reversible long-term hormonal contraception in the UK. Pharmacoeconomics 2004;22:1141-51.
25. D'Arcangues C. Worldwide use of intrauterine devices for contraception. Contraception 2007;75(6 Suppl):S2-7.
26. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006;73:145-53.
27. Van Houdenhoven K, van Kaam KJ, van Grootheest AC, Salemans TH, Dunselman GA. Uterine perforation in women using a levonorgestrel-releasing intrauterine system. Contraception 2006;73:257-60.
28. Prager S, Darney PD. The levonorgestrel intrauterine system in muciparous women. Contraception 2007;75 Suppl 6:S12-5.
29. Inki P. Long-term use of the levonorgestrel-releasing intrauterine system. Contraception 2007;75 Suppl 6:S161-6.
30. Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007;75 Suppl 6:S16-30.
31. Davidoff F, Trussell J. Plan B and the politics of doubt. JAMA 2006;296:1775-8.
32. Ngai SW, Fan S, Li S, Cheng L, Ding J, Jing X, et al. A randomized trial to compare 24 hour versus 12 hour double dose regimen of levonorgestrel for emergency contraception. Hum Reprod 2005;20:307-11.
33. American Academy of Pediatrics. Policy statement on emergency contraception. Pediatrics 2005;116:1038-47.
34. Gold MA, Sucato GS, Conard LA, Hillard PJ, and the Society for Adolescent Medicine. Provision of emergency contraception to adolescents. J Adolesc Health 2004;35:67-70.
35. American College of Obstetricians and Gynecologists. ACOG practice bulletin: emergency oral contraception. Number 25, March 2001 (replaces practice pattern number 3, December 1996). Int J Gynaecol Obstet 2002;78:191-8.
36. Raine TR, Harper CC, Rocca CH, Fischer R, Padian N, Klausner JD, et al. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs: a randomized controlled trial. JAMA 2005;293:54-62.
37. Jackson RA, Schwarz EB, Freedman L, Darney P. Advance supply of emergency contraception: effect on use and usual contraception. A randomized trial. Obstet Gynecol 2003;102:8-16.
38. Glasier A, Baird D. The effects of self-administering emergency contraception. N Engl J Med 1998;339:1-4.
39. Ranjit N, Bankole A, Darroch JE, Singh S. Contraceptive failure in the first 2 years of use: differences across socioeconomic subgroups. Fam Plann Perspect 2001;33:19-27.